IMPRINT
Pantarhei Oncology BV | Boulevard 17 | 3707 BK Zeist | The Netherlands
Phone: +31 (0)30 6 985 020 | Email: info@pantarheioncology.nl
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by Pantarhei Oncology and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
SOCIAL MEDIA
© 2019
Pantarhei Oncology Change of Address
/in News /by Pantarhei Oncology BVBeginning of September, Pantarhei Oncology has moved the office to a new building. The new address is Boulevard 17, 3707 BK Zeist, the Netherlands. For more information, see change-of-address.
12th European Congress on Menopause and Andropause, May 15-17, 2019, Berlin
/in News /by Pantarhei Oncology BVOn Thursday May 16, 2019, Pantarhei Oncology sponsored a symposium entitled “Treatment of Breast Cancer and Prostate Cancer with the Fetal Estrogen Estetrol”. Lectures were presented by Herjan Coelingh Bennink (The profile of the fetal estrogen estetrol [E4]), Hans Georg Lenhard (Treatment of advanced breast cancer with E4) and Frans Debruyne (Treatment of advanced prostate cancer with E4). The session was chaired by Tomasso Simoncini and Yvette Zimmerman.
Interview met Yvette Zimmerman en Olav Andriesse in BiotechNEWS & Life Sciences
/in News /by Pantarhei Oncology BVPantarhei Bioscience (sinds 2001) werd in 2014 uitgebreid met een succesvolle Oncology-tak en diende in de afgelopen jaren meer dan 220 patenten in. Een actieve onderneming, volop in ontwikkeling -niet voor niets Panta Rhei – alles stroomt- met een diepgewortelde missie en visie: “Pantarhei ontwikkelt veilige en effectieve nieuwe geneesmiddelen op basis van bestaande menselijke moleculen tot en met “proof-of-concept” bij de mens. Met deze strategie zijn we 18 jaar geleden begonnen en is succesvol gebleken,” aldus de nieuwe CEO Yvette Zimmerman. Lees hier het artikel.